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ABSTRACT 
Current concepts concerning nicotine's central nervous 
system (CNS) mechanism(s) of action suggest that this drug 
is producing its effects via an interaction at nicotinic-
cholinergic receptors (nAChRs) which open a membrane cation 
channel. Following initial opening of the channel, nicotine 
appears to induce a rapid desensitization of the nAChRs, 
closing the channel and resulting in a cessation of 
nicotine's effects. Research presented here will provide 
evidence of this secondary desensitization process in vivo 
by demonstrating nicotine's ability to induce acute 
tolerance in the discriminative stimulus (DS) paradigm. The 
ability of nicotine to elicit DS control of behavior was 
significantly reduced via challenge doses of (800, 1200, and 
1600 ugjkg, s.c.) of nicotine administered 60-180 minutes 
prior to the training dose (400 ugjkg, s.c.). Eight out of 
twenty rats demonstrated this phenomena, with time and dose 
varying, suggesting that these effect may be contingent upon 
the individual rat studied. It appears that we have found a 
means of investigating cellular mechanisms in vivo using 
operant behavior. 
INTRODUCTION 
Since the mid 1960's one of the hottest areas of 
central nervous system research has dealt with the 
mechanisms of action of neurotransmitters and their 
endogenous and/or exogenous ligands. Nicotine has drawn the 
attention of researchers because of its agonist effect upon 
the neurotransmitter acetylcholine. Researchers have shown 
that there are functional receptors for nicotine in both the 
peripheral and central nervous systems. 
The use of in vitro and in vivo studies is reviewed in 
relation to acute tolerance (desensitization). An attempt 
is made to integrate these in vitro and in vivo studies into 
a meaningful analysis of acute tolerance (desensitization) 
in the brain. The emphasis of this analysis is through the 
use of time and dose to develop a better understanding of 
the mechanism(s) of action leading to acute tolerance 
(desensitization). The discussion will suggest that the 
mechanism(s) of action is(are) individually specific, and 
may be useful in the determination of why individual people 
abuse drugs. 
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CHAPTER ONE 
A BRIEF HISTORY: 
Commercial cultivation of tobacco began in the United 
States in 1612, at Jamestown, Virginia, and soon became the 
major cash crop in the Colonies. Tobacco was used to pay 
taxes and often the salaries of public officials (Encyclopedia 
Americana, 1987). The use of tobacco rapidly spread through-
out the world and in 1984 the United States alone produced 
tobacco products in excess of 17 billion dollars (U.S. Bureau 
of the Census, 1987). 
Research to determine the component(s) of tobacco 
responsible for its pharmacological effects began in the 
1800's. cerioli and Vanguelin were the first to isolate 
nicotine from tobacco; they named it "nicotianine". In 1828, 
Posselt and Reiman purified the compound and renamed it 
"nikotin", which was first synthesized during the 1890 's (U.S. 
Dept. of Health and Human Services, 1988). Langley and 
Dickinson (1889) were first to report on the stimulating and 
"paralysing" effects of nicotine on the autonomic nervous 
system (ANS) , a finding which played a central role in 
characterizing the physiology of the mammalian autonomic 
nervous system. Further work led to the realization that 
large doses of nicotine were able to block the stimulation of 
ganglion cells (Langley and Anderson, 1895; Langley, 1886, 
1911). Langley in 1914 showed that the skeletal muscle 
effects of nicotine were similar to acetylcholine and could be 
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blocked by curare. Dale (1914) was further able to distinguish 
two mech8¥lsmelm~eaaetion. Dale, using a spinal cat also, 
showed that atropine blocked the action of muscarine, but was 
unable to block the action of nicotine. Thus, Dale was first 
to recognize two sites of acetylcholine action, a "muscarinic" 
and a "nicotinic" site (For a review see Goodman & Gi llman, 
(1975)). Since these early classical studies concerning the 
ANS, much research has been focused towards learning more 
about sites of action of drugs such as nicotine and muscarine. 
From this concentrated effort we now realize that these drugs 
act on specific receptors which are innervated by neurons 
which release the neurotransmitter, acetylcholine (ACh). The 
state of the relationships between ACh and these cholinergic 
receptors is characterized in Fig.1. 
CHAPTER TWO 
MOLECULAR MECHANISMS OF ACETYLCHOLINE AND NICOTINE ACTION: 
The overriding hypothesis from earlier work with nicotine 
suggested that this drug acted at specific sites also sensit-
ive to acetylcholine. At this point, nicotine is thought to 
mimic acetylcholine, or act as though acetylcholine (ACh) was 
released onto a specific acetylcholinergic site or receptor. 
Thus, nicotine is classified as a cholinergic drug, and to 
better understa~d nicotine's effects we need to first look at 
acetylcholine and how it produces its effects. Katz & Thesleff 
(1957) proposed, that in addition to acetylcholine's action as 
an agonist, it can also act as an antagonist at the same 
FIGURE 1 
A schematic comparison of nicotinic and J1UScarinic 
Cholinergic neurons. 
The n-AChR is viewed as linked to a cation channel, while the 
m-AChR medicates its effects via a second messenger, IP, or c-
AMP. Redrawn from Shephard (1988). 
cholinergic sites via a desensitization mechanism. 
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These 
workers were able to show that acetylcholine could induce a 
desensitization of the nerve-muscle motor end-plate "when the 
drug concentration was maintained for a sufficiently long 
time." It was further shown that desensitization resulted in 
an extended refractory period that only slowly recovered after 
the removal of acetylcholine. It was theorized that desensi-
tization of the receptor was due to a change from an active 
form of the receptor site to an inactive form. Acetylcholine 
was postulated as having a higher affinity for the inactive 
state than the active state which was used to explain how 
small doses of acetylcholine were able to facilitate the 
desensitization of the receptor. This early analysis of 
desensitization was supported by the work of Fatt (1950) who 
showed that the concentration of drug was important in the 
rate of development of desensitization. 
Ochoa et al (1989) have presented a more recent view of 
nicotinic-cholinergic receptor (n-AChR) desensitization that 
incorporates the basic concepts put forth earlier by Katz & 
Thesleff ( 1957). The model suggests that the synaptic release 
of acetylcholine first interacts with the n-AChR to form an 
activated state. The activated state then opens a cation 
channel on the postsynaptic membrane, which allows the influx 
of positively charged molecules (Fig. 2) . The n-AChR is 
theorized to be rapidly converted to a deactivated state, thus 
closing the cation channel. 
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Ochoa suggested that this process may be important in 
learning and memory deficits as well as myasthenia gravis. It 
further seems that the desensitization process has a physio-
logical role as a means of turning off the nAChR if too much 
ligand is released. on the other hand, this process is 
utilized each day in our use of insecticides in which the 
acetylcholinesterase inhibitors (prevent the physiological 
breakdown of ACh) will elicit an elevation of ACh to a point 
of desensitization, killing the insect attacked. The increase 
in ACh induces a paralysis of respiratory and other muscles 
which kills the animal. It might also be mentioned that this 
is also the basis for the use of "War Gases" by the military. 
In vitro studies have also provided us with abundant 
evidence that nicotine causes a release of acetylcholine 
through the opening of a cation channel in close proximity to 
select nicotinic receptors. The opening of this cation 
channel allows the influx of one or more of the positively 
charged components of the extracellular fluid. It is a 
relatively large channel containing many negatively charged 
molecules that results in a slow influx. The nicotinic 
receptor is rapidly desensitized resulting in the channel 
being in the open state for a very short period of time. 
Armitage (1969), was one of the first to show that nicotine 
could cause the release of acetylcholine in the brain, and 
Macintosh & Osporin (1953) and Mitchell (1963) have shown that 
acetylcholine is released from the cerebral cortex which has 
FIGURE 2 
Mechanisms of nAChR desensitization. 
This figure presents an idealized nicotinic cholinergic 
synaptic junction containing acetylcholine (black dots) 
contained within synaptic vesicles (in circles) and 
postsynaptic membrane (From Ochoa et. al., 1989). 
A- Receptor exists in an equilibrium condition of a 
mixture of two forms: resting (R) and desensitized (D) 
states. 
B- An action potential facilitates the release of ACh. The 
result is a sudden increase in ACh concentration at the 
synaptic cleft and occupies one of the receptor states, 
R and D. This induces a conformational change, which 
leads to the activated state (A, in which the channel 
opens allowing cation movements essential for the 
development of a postsynaptic action potential. As soon 
as ACh occupies, the affinity of the receptors toward ACh 
and the D state is promoted, resulting in the termination 
of the action of ACh. 
A 
I 
• • • • 
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led to further research suggesting that nicotine might cause 
the release of acetylcholine at several central nervous system 
(CNS) sites (Armitage & Hall, 1967; Armitiage, Milton & 
Morrison, 1966; Morrison, 1968). 
In vitro electrophysiological studies using nicotine as 
a ligand have repeatedly shown that a particular type of 
cholinergic receptor can be easily and rapidly desensitized 
(Bertrand, Ballivet, & Rungger, 1990; Zaimis & Heads, 1976; 
Sumikawa & Miledi, 1989; Adams, 1987; Ogden & Colquhoun, 1985; 
Adams, 1975; Chabala, Gurney, & Lester, 1986; Neher & Sakmann, 
1975). Desensitization has been shown to last from 10 to 20 
minutes. The evoked currents generated by nicotine generally 
are not distinguishable from acetylcholine evoked currents. 
The In Vivo work by London (1990) has also shown that nicotine 
appears to act on select brain area receptors sensitive to 
acetylcholine (nicotinic-acetylcholinergic receptors; 
nAChR's). Using the 2-deoxy-D--[l-14C] glucose method for the 
identification of central cellular (and brain area activity) 
activity following the injection of acute systemic (-) 
nicotine, London showed that a significant stimulation of 
several brain areas were associated with both ['H] nicotine 
and ['H] ACh binding sites. The increased nicotine-induced 
activity was also attenuated by mecamylamine, a non-competi-
tive nicotine antagonist which is selective for the nAChR. 
Evidence that nicotine can elicit a rapid desensitization 
following its agonist effect at the nAChR in vivo has also 
9 
been provided by Sharp and Beyer (1986). These workers showed 
that acute doses of nicotine were able to inhibit the release 
of adrenocorticotropin and prolactin. Stimulation of the 
adrenocorticotropin-corticosterone and prolactin axes had 
threshold i.p. injections ranging from 100 to 250 ug/kg ((-) 
nicotine). A single dose of nicotine (500 ug/kg i.p.) caused 
an acute desensitization of the stimulatory effects, when a 
second injection (1000 ug/kg i.p.) was administered one hour 
later. This desensitization lasted for 6 hours. Hulihan-
Giblin, Lumpkin and Kellar (1990) replicated the study of 
Sharp and Beyer using 100 ug/kg i.v . nicotine. The prolactin 
release had returned to normal within 24 hours. Hulihan-
Giblin, Lumpkin and Kellar (1990) using chronic dosing (10 
days twice a day) of nicotine (800 ug/kg s.c.) abolished the 
release of prolactin, when an acute dose of nicotine (60 ug/kg 
i. v. ) was given 2, 6, or 8 days after the last chronic 
injection. Prolactin release had returned to normal after 14 
days from the last chronic injection. 
Thus, these studies provide much data that nicotine 
appears to be acting at neuronal sites sensitive to acetylcho-
line, suggesting that nicotine ultimately is producing its 
pharmacological effects by mimicking this endogenous transmit-
ter. In addition, this work also suggests that nicotine is 
capable of inhibiting the same receptors via a desensitization 
process similar to that ascribed for the cholinergic endoge-
nous ligand, acetylcholine. Interestingly, this desensitiza-
10 
tion process appears to be specific to the nAChR and does 
appear to occur at the mAChR (Fig. 1). 
CHAPl'ER THREE 
EFFECTS OF NICOTINE ON BEHAVIOR: NICOTINE AS A 
DISCRIMINATIVE STIMULUS (DS) 
Stolerman (1990) has shown that initial dosing of rats 
with nicotine causes an increase in rates of responding of 
conditioned behavior to avoid aversive stimuli or to obtain 
reward. Repeated dosing produces the development of tolerance 
and a reduction in responding in the same paradigms. Nicotine 
is also capable of increasing rates of responding in locomotor 
tasks, with a similar tolerance and reduction of responding 
developing rapidly. stolerman (1989) and Rosecrans (1989) 
have both shown that this tolerance can develop even after 
only a single dose. Maze running speed and percent correct 
moves are improved by preinjections of nicotine. It would 
appear that all of these phenomena are mediated by one 
receptor type since mecamylamine is capable of blocking all 
these behavioral tasks. Nicotine is also a drug noted for its 
ability to induce biphasic effects with a great deal of 
behavioral and pharmacological variability between subjects 
(Battig & Shlatter, 1978; Bovet, Bovet-Nitti, & Oliverio, 
1967; Domino, 1967; Marks & Collins, 1985; Morrison & 
Armitage, 1967; Rosecrans, 1971; Clarke & Kumar, 1983; Ksir, 
Hakan, Hall & Kellar, 1985; Nordberg, Wahstrom, Arnelo, & 
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Larsson, 1985; Rosecrans & Chance, 1977). 
The drug discrimination paradigm has had special rele-
vance to research in the nicotine area as it not susceptible 
to many of nicotine's variable and individual effects on 
behavior. This procedure has proved to be an effective 
methodology for determining an animals 'subjective' assessment 
of a drug . This 'subjective' assessment by the animal is 
created by the development of a relationship between a drug 
and a particular behavior. The drug then acts as the discrim-
inative stimulus for the behavior. In a typical drug discrim-
ination study the animal is trained to detect the difference 
between a specific drug and vehicle. Drug discrimination 
requires the animal, while in an operant chamber, to press one 
lever when under the influence of the drug and the other lever 
when in the non-drug state. Thus, the animal emits a behav-
ioral response under the stimulus control of the drug for a 
reward (Fig. 3). 
The discriminative stimulus properties of drugs affecting 
n-AChR' s is distinct from other AChR' s. Arecoline is an 
agonist at m-AChR's and is antagonized by atropine, but is not 
active at n-AChR's and is not antagonized by mecamylamine. 
Nicotine is selective to n-AChR's and is antagonized by 
mecamylamine, but not atropine (Rosecrans, 1989; Stolerman, 
1987). Meltzer & Rosecrans (1988) showed that physostigmine 
(an acetylcholinesterase inhibitor) generalized to the m-AChR 
via an increase of brain ACh at this site, but not to the n-
FIGURE 3 
A description of the drug discrimination paradicpa 
This figure presents the steps to training a rat to 
discriminate a specific Nicotine (400 ug/kg, s.c.) from the 
non-drug (vehicle) state. Once rats learn the specific to 
discriminated Nicotine from Vehicle they can then be evaluated 
in relation to mechanisms of drug action. This takes place 
during Test Sessions in which responding by the rat is 
recorded on each lever and data is collected in relation to l 
Nicotine-correct Lever responses. Generalization can be 
conducted using a variety of Pharmacological and Biobehavioral 
interventions (From Rosecrans, 1989). 
TRAINING 
DMJG•COM!CT 
L.!VU 
GENERALIZATION -TDT 
SESSION 
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AChR. This result suggests that the mechanism of action of 
nicotine may have components not directly linked to the 
cholinergic system. 
In addition, Stolerman (1989) has shown that rats trained 
to 100 ug/kg (-) nicotine in a drug discrimination paradigm 
generalized to(+) amphetamine (a dopamine receptor agonist). 
Chance et. al. (1977) has additionally shown only partial 
generalization to (+) amphetamine in rats trained to discrimi-
nate several training doses (100- 400 ug/kg (-) nicotine) 
training under different schedules of reinforcement. These 
latter studies are extremely important as they suggest that: 
(1) there may be a dopaminergic component in the discriminat-
ive stimulus, and (2) that because of nicotine's known 
biphasic nature in behavioral studies (see Refs. above) one 
needs to consider a wide range of doses when examining 
nicotine's actions. 
The basic objective of this research was to further 
evaluate nicotine's mechanism of action, and to specifically 
determine whether nicotine can be shown to exhibit in vivo 
desensitization (acute tolerance) to its OS. The overall 
design of this research evaluated the ability of nicotine (400 
ug/kg, s.c.) to act as a OS when challenged with a different 
doses of nicotine (800-1600 ug/kg., s.c.). The challenge dose 
was administered at various times ( 15-240 min.) prior to 
testing the ability of a rat to detect the nicotine ( 400 
ug/kg., s.c.) training dose. Two experiments were conducted. 
14 
The first experiment was designed to characterize nicotine-
induced acute tolerance in the rat in which the tolerance-
eliciting dose was held constant over a predetermined time 
course. The second experiment varied the tolerance-eliciting 
dose to evaluate the dose-response as well as the time-
duration nature of acute tolerance (desensitization). 
CHAPTER FOUR 
EXPERIMENT ONE: A CHARACTERIZATION OF NICOTINE-ELICITED 
ACUTE TOLERANCE (DESENSITIZATION) OF THE NICOTINE 
DISCRIMINATIVE STIMULUS (OS) 
INTRODUCTION 
The research of Domino (1967) has been central to our 
quest to determine how nicotine affects behavior. He essen-
tially showed that the behavioral effects of nicotine are 
elicited by an agonist effect at a central nicotinic-choliner-
gic receptor. Domino further suggested that the nicotinic-
cholinergic receptor (nAChR) significantly differed from the 
mAChR, but that both receptor types were responsive to the 
endogenous neurotransmitter, acetylcholine. In vitro studies 
(Bertrand, Ballivet, & Rungger, 1990; Zaimis & Heads, 1976; 
Sumikawa & Miledi, 1989; .Adams, 1987; Ogden & Colquhoun, 1985; 
Adams, 1975; Chabala, Gurney, & Lester, 1986; Neher & Sakmann, 
1975) have supported this hypothesis and have shown a direct 
link between acetylcholine and nicotine. In viyo research 
conducted by Meltzer and Rosecrans (1988), on the other hand, 
has suggested that the relationship between nicotine and 
15 
acetylcholine was not as symbiotic as we would like to think . 
They showed that rats trained to discriminate (-) n i cotine 
(400 ug/kg) from saline failed to generalize to physostigmine 
(125 ug/kg-250ug/kg), a cholinesterase inhibitor that retards 
the metabolism of acetylcholine. Rosecrans ( 1965) showed that 
these doses of physostigmine raised acetylcholine levels in 
the brain. Arecoline (a muscarinic (mAChR agonist) trained 
rats did generalize to physostigmine and the generalization 
was blocked by atropine (muscarinic antagonist). The question 
then becomes why does the increase of acetylcholine trigger 
the discriminative stimulus cue of a muscarinic drug, but not 
that of nicotine? Is the nicotinic cue regulated by more than 
one receptor system, or is the nicotinic cue somehow altered 
by a receptor transformation? 
In vivo studies by Marks and Collins (1990) have shown 
that there is an up-regulation of nicotinic receptors after 
chronic administration of nicotine. Unlike the classic 
receptor theory, that states that chronic exposure to an 
agonist should result in the down-regulation of receptors, 
nicotine induces an up-regulation. Wonnacott ( 1990) has 
hypothesized that this up-regulation is the result of some 
form of a functional antagonism which might explain why 
nicotine does not generalize to physostigmine. Physostigmine 
causes a rapid increase in extracellular acetylcholine which 
may result in a rapid desensitization of the nicotinic 
receptor. Thus, physostigmine might be inadvertently inducing 
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a "functional antagonist state" recorded by rat subject as a 
generalization to vehicle, or the non-drug state. 
From this, it was hypothesized that the drug discrimina-
tion paradigm might be an effective method to test the 
desensitization hypothesis by assessing acute tolerance 
involving both nicotine and physostigmine. The time course 
paradigm would allow us to evaluate i n vivo the effects of 
nicotine over time on the nicotinic acetylcholinergic recep-
tor. Furthermore, the paradigm would allow us to assess the 
role of physostigmine in the acute tolerance phenomena. 
The first phase of the experiment evaluated the ability 
of (-) nicotine (800 ug/kg) to functionally antagonize the 
ability of a rat to recognize the training dose of ( - ) 
nicotine (400 ug/kg). Acute tolerance (desensitization) was 
exhibited by 48% of the rats and 52% exhibited no acute 
tolerance (desensitization). The second phase of the experi-
ment assessed the generalization of physostigmine to nicotine, 
and physostigmine's ability to antagonize the discriminative 
stimulus effect of nicotine. In addition nicotine's sensitivi-
ty as a OS, and the ability of mecamylamine and the mAChR 
antagonist, scopolamine, to antagonize the nicotine OS, was 
also evaluated as function of the ability of each subject to 
exhibit acute tolerance to nicotine. 
METHODS 
SQBJEC'fS; 
Twenty-five male Sprague-Dawley rats (175-225 g) obtained 
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from Dominion Laboratories, Dublin, Virginia served as 
experimental subjects throughout this investigation. Rats 
were housed individually under a 12 hour light/dark regime 
(800-2000 hrs. light) in a temperature controlled colony room 
( 22°C). Animals were maintained on a diet (Purina Rodent 
Chow) that restricted their body weight to approximately 85% 
of their free feeding weight. Water was available ad libitum 
in the home cages. 
TRAINING PROCEDURE: 
A two lever operant drug discrimination paradigm VI 15 
was used in this study. One stainless steel wall of each 
chamber contained two stainless steel levers separated by a 
food tray. Illumination was provided by a white light placed 
directly above the food tray in the BRS chambers used for this 
research. Illumination in the Lafayette chambers used was 
provided by a white light directly above each lever. The 
chambers were housed in sound and light attenuating cubicles. 
Exhaust fans provided ventilation and white noise during 
sessions. Data was automatically collected by two Commodore 
64 micro-computers. Two 32-line opto-isolated I/O interfaces 
(Rayfield Equipment Ltd., Waitsfield, VT) each controlled 
operation of four chambers. Software used to independently 
control chambers was the Programmers Micro Application 
Language (PROMAL, Raleigh, NC). 
Rats were, trained to respond on one lever after a 
subcutaneous (s.c.) injection of(-) nicotine (400 ug/kg) and 
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the other lever after a s.c. injection of 0.9% saline. Rats 
were placed in an operant chamber (4 Lafayette model 80001 
chambers and 4 BRS/LVE model sec 002 chambers) 5 minutes after 
injections. Reinforcement was a Bioserv 45 mg precision 
dustless pellet. 
Animals were initially placed in operant chambers with 
both levers present. An FR-1 schedule was used until the 
animal was responding 75 to at least 100 times in a 30 minute 
session. During the initial training period animals were 
reinforced only if they responded on the vehicle correct lever 
in which half of the animals were trained to press the right 
lever for vehicle and the left lever for drug, and the other 
half were trained to the reverse pattern. Training progressed 
from the FR-1 to a VI-3 on the vehicle correct lever. After an 
animal was responding between 75-100 times during a 30 minute 
session the schedule was increased to VI-5, 8, 12, and finally 
VI-15. Training sessions were decreased to 15 minutes once an 
animal had reached VI-3. Animals were then maintained on the 
VI-15 schedule for one week. The following week animals were 
injected daily with vehicle (lml/kg) 5 minutes before being 
placed in the operant chamber. Animals were reinforced on the 
training lever (vehicle lever). The following week animals 
were injected with 400 ug/kg of (-) nicotine 5 minutes prior 
to being placed in the operant chamber. These animals were 
required to switch levers to obtain reinforcement. The 
following week a double alternation schedule consisting of 
19 
vehicle two days and nicotine two days was initiated and were 
run 5 days a week. Animals learned to discriminate nicotine 
from vehicle in 40 to 80 training sessions. 
CRITERIA TESTING: 
Animals were required to meet a criteria of three 
successive days of 80% or greater correct lever responding 
during specific Check Sessions before the initiation of 
specific experiments were begun. The criteria testing 
sessions were conducted during two minute check sessions, in 
which neither lever was reinforced for lever pressing (extinc-
tion sessions) • Check sessions were coupled with training 
sessions of thirteen minutes. During the training portion of 
the session, the animal was reinforced for pressing the 
appropriate drug-correct lever. 
Experimental subjects that met criteria ,i.e. pressed 80% 
or greater on the correct lever during three consecutive check 
sessions were considered ready for testing the following day. 
This schedule resulted in Wednesday being a training day. 
GENERAL TESTING: 
All data was collected during specific Test sessions 
which were identical to the Check Session in duration (two 
minutes) and were conducted in extinction; however, unlike the 
check sessions there was no training component. 
DOSE RESPONSE EXPERIMBNTS: 
Initial testing assessed the dose-effects of (-) nicotine 
(50, 100, 200, 400, 800 ug/kg) under the VI-15 schedule. 
20 
Injections were given 5 minutes prior to placing the animal in 
the operant chamber. The schedule of injections was deter-
mined using a Latin Square design. 
NICOTINE ANTAGONISM EXPERIMENTS: 
Rats were then assessed for behavioral effects of 1000 
ug/Rg of racemic mecamylamine in conjunction with their 
training dose of (-) nicotine. Mecamylamine was administered 
5 minutes prior to the injection of (-) nicotine. Animals 
were also tested for the behavioral effects of 100 ug/kg 
scopolamine, using the previous procedure except the animals 
were injected 10 minutes prior to the (-) nicotine injection. 
NICQTINE-INDUCED ACUTE TOI.ERANCE EXPERIMENTS: 
Acute tolerance (desensitization) testing required that 
animals be injected on eight test days at the following time 
points 15, 30, 60, 90, 120, 150, 180, and 210 minutes, prior 
to being injected with the training dose of 400 ug/kg of (-) 
nicotine. A Latin Square design was used to determine the 
time point order for each test day. Animals were considered 
to exhibit acute tolerance (desensitization) if % nicotine-
correct responding was reduced by 50% or greater. 
RESULTS 
Table la presents the overall results for the 
desensitizing group and table lb presents the overall results 
for the non-desensitizing group evaluated in this research: 
(1) the percent reduction of responding on the nicotine lever 
induced by the nicotine challenge ( 800 ug/kg, s. c.), ( 2) 
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replication of percent reduction of responding on the nicotine 
lever, (3) Effective dose 50% (ED-50, 50% nicotine-correct 
lever responding) of each rat determined via a dose-response 
evaluation, (4) average response rate, (5) percent antagonism 
by mecamylamine, and (6) percent antagonism by scopolamine. 
For a variety of reasons, not all subjects were not tested for 
either mecamylamine and/or scopolamine antagonism. Twelve of 
the twenty-five rats exhibited acute tolerance 
(desensitization) at one or more time point(s). Individual 
rats were re-tested at their individual peak time point(s) 
(Figures 4-6). The group that did not show acute tolerance 
(non-desensitizers) exhibited a potentiation (% correct 
nicotine responding) from the double dosing (Figure 7). On 
the other hand, the desensitizing group responded below 
individual training levels at all time intervals evaluated 
(Figure 8) • overall response rates were less in the non-
desensi tizing group when compared to the desensitizing group; 
this relationship was not statistically significant (Figure 
9). The 90 and 120 minute time intervals were the most 
prominent time periods for desensitization. The median range 
of acute tolerance (desensitization) at the 90 and 120 minute 
time points for the desensitization group was 41%. The median 
range of acute tolerance (desensitization) at the 90 and 120 
minute time points for the non-desensitizing group was 8%. 
The overall difference between the desensitizing and non-
desensitizing groups was significant (F [1,19]=52.5; ~<0.001). 
22 
Seven rats from the first phase of the experiment were 
tested for acute tolerance (desensitization) following a 
preinjection of physostigmine ( 125 ug/kg). Three of the rats 
were classified as desensitizers and four were classified as 
non-desensitizers. Rats followed the same patterns of 
responding after the preinjection of physostigmine as they had 
following the preinjection of nicotine (Figures 10-13). 
DISCUSSION 
The analysis of variance produced a significant differ-
ence in the variable group. This finding supports the 
contention that acute tolerance (desensitization) to nicotin-
e's discriminative stimulus can be demonstrated in a subpopul-
ation of rats. All rats in the study received a minimum of 
sixty injections before acute tolerance (desensitization) 
testing ( 400 ug/kg nicotine). Whether these rats were also 
chronically tolerant is difficult to say. However, these 
results also suggest there should be some chronic tolerance 
which may indicate that there are separate mechanisms for 
acute and chronic tolerance, at least in relation to the 
nicotine DS. 
Chronic tolerance represents a physiological change in an 
organism over an extended period of time. There is likely a 
permanent change in receptors; in the case of nicotinic 
receptors an up-regulation (Marks and Collins, 1985). 
However, acute tolerance represents a temporary change in 
receptor activity in response to a specific ligand. Nicotine 
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appears to be able to rapidly transform an active receptor 
into an inactive receptor as evidenced in the desensitization 
group. In the inactive state the discriminative stimulus 
properties of nicotine appear to be inhibited. Interestingly, 
this inhibition appears to be specific to individual rats and 
lasts for varying times. The rats that failed to exhibit 
acute tolerance (desensitization) actually showed a potentia-
tion of the discriminative stimulus. 
One important facet of any behavioral task is the 
evaluation of response rates. Nicotine historically has shown 
biphasic locomotor effects (Battig & Shlatter, 1978; Bovet, 
Bovet-Nitti, & Oliverio, 1967; Domino, 1967; Marks & Collins, 
1985; Morrison & Armitage, 1967; Rosecrans, 1971; Clarke & 
Kumar, 1983; Ksir, Hakan, Hall & Kellar, 1985; Nordberg, 
Wahstrom, Arnelo, & Larsson, 1985; Rosecrans & Chance, 1977). 
There were no significant differences between rates of 
responding for the two groups. The 15 and 30 minute time 
periods did show reduced responding, these effects were seen 
in both groups, and were considered an inability of the rats 
to cope with high blood concentrations of nicotine. 
The mecamylamine and scopolamine results were as expected 
and produce9 no differences between groups. The failure of 
physostigmine to generalize to the discriminative stimulus of 
nicotine has been seen repeatedly in this laboratory and 
others (Stolerman, 1987), but the ability of physostigmine to 
mimic nicotine in the acute tolerance (desensitization) 
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phenomena suggests that this drug is inducing a desensitized 
nAChR analogous to that induced by nicotine. Katz and 
Thesleff (1957) hypothesized that nicotine had a higher 
affinity for the inactive form of the nicotinic acetylcholine-
rgic receptor than the active form. This could be an explana-
tion for the ability of physostigmine to mimic nicotine in the 
acute tolerance (desensitization) experiment, but not general-
ize significantly to discriminative stimulus properties of 
nicotine. Physostigmine may cause a rapid desensitization of 
the nicotinic receptor in vivo resulting in rats generalizing 
to the vehicle state. 
The study raised two questions that needed further 
evaluation. In addition to time being a factor in the demon-
stration of acute tolerance (desensitization) it seems 
plausible that the concentration of dose should also be a 
factor. Furthermore, it is also possible that all rats would 
show acute tolerance if challenged with a high enough dose 
suggesting that we may be measuring rate of tolerance develop-
ment which is not so "all or none". The lack of a dose 
response effect at the completion of the experiment also 
raised the question of permanent physiological changes due to 
the nicotine dosing paradigm. Thus, this research has 
demonstrated that acute tolerance to nicotine is 
demonstratable and replicable in the same animal subject, and 
has many implications in relation as to how nicotine affects 
behavior. The finding that a select group of rats are not able 
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to exhibit acute tolerance is extremely important and suggests 
that some rats may differ in relation to central nAChR 
machinery. 
CHAPl'ER FIVE 
EXPERIMENT TWO: IX>SE-RESPONSE RELATIONSHIPS OF 
NICOTINE-ELICITED ACUTE TOLERANCE (DESENSITIZATION) 
OF THE NICOTINE DISCRIMINATIVE STIMULUS (DS) 
INTRODUCTION 
This study was designed as a follow-up to Experiment One, 
and to determine the dose-response characteristics of nico-
tine-elicited acute tolerance (desensitization). In the first 
experiment, acute tolerance (desensitization) was demonstrated 
after a preinjection dose of 800 ug/kg of nicotine (challenge 
dose) followed by an injection of 400 ug/kg (training dose) of 
nicotine. That is, nicotine was capable of inducing acute 
tolerance, which appears evident in a select population of 
rats studied. Overall 52 percent of the rats studied in 
Experiment One were unable to exhibit desensitization to 
nicotine. Being aware of the acute tolerance effects of 
nicotine, it was now important to determine if rats that 
failed to show acute tolerance did so because the challenge 
dose was too small. If so one should be able to demonstrate 
acute tolerance (desensitization) if the preinjected doses of 
nicotine were higher. 
The hypothesis presented suggests that rats which failed 
to demonstrate acute tolerance (desensitization) at 800 ug/kg 
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of (-) nicotine might show tolerance at either or/both 1200 
ug/kg or 1600 ug/kg. 
METHODS 
The subjects and drug discrimination procedures utilized 
in this study were essentially identical to that of EXPERIMENT 
ONE. Significant differences will be specifically discussed 
were they occur. Acute tolerance (desensitization) testing 
required that animals be injected on five test days (per dose) 
at the following time points 60, 90, 120, 150, and 180 
minutes, prior to being injected with the training dose of 400 
ug/kg of (-) nicotine. A Latin Square design was used to 
determine the time point order for each test day. Animals 
were considered to exhibit acute tolerance (desensitization) 
if their percent nicotine correct lever responding was 
antagonized by 50% or greater. There were some modifications 
from Experiment One. First, solutions used in this study were 
buffered (vehicle, pH 7.4 phosphate solution; nicotine, Ph 
7.4); and second the 15, 30, 210 time periods were not used. 
In addition to acute tolerance determinations at each 
challenge dose, dose-response nicotine generalization studies 
were conducted both Before and After completion of the acute 
tolerance research. 
RESULTS 
Data were analyzed using the split-plot analysis of 
variance model on PCA Anova. The overall mean percent correct 
nicotine responding was 78. 5. The mean percent correct 
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nicotine responding for the desensitized group was 62.0. The 
mean percent correct nicotine responding for the non-desensi-
tized group was 78. 7. The overall mean response rate per 
second was 0.17. The mean response rate for the desensitized 
group was 0.12. The mean for the non-desensitized group was 
0.19. Table 4 and 5 report results for all conditions. 
Figure 14 reports the percent correct nicotine responding 
for the between subject variable group (F=13.568; Q<0.0020), 
and the response rate for the between subject variable group 
(F=3.009; Q<0.0968). Figure 15 reports the percent correct 
nicotine responding for the within subject variable dose 
(F=ll.156; Q<0.0003), and the response rate for the within 
subject variable dose (F=3.568; Q<0.0377). Figure 16 reports 
the percent correct nicotine responding for the within subject 
variable time (F=ll.05; Q<0.0000), and the response rate for 
the within subject variable time (F=4.677; ~<0.0024). Figure 
17 reports the percent correct nicotine responding for the 
interaction between dose and time (F=27.225; Q<0.0000), and 
the response rate for the interaction between dose and time 
(F=l0.583; Q<0.0000). Figure 18 reports the percent correct 
nicotine responding for the interaction between group and dose 
(F=6.097; ~<0.0055), and the response rate for the interaction 
of group by dose (F=l.110; Q<0.3412). Figure 19 reports the 
percent correct nicotine responding for the interaction of 
group by time (F=2.0ll; Q<0.1012), and the response rate for 
the interaction of group by time (F=0.513). Figure 20 reports 
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the percent correct nicotine responding for the interaction of 
group by dose by time (F=l.706; 2<0.1014), and the response 
rate for the interaction of group by dose by time (F=0.975). 
Figure 21 reports the dose response data for percent correct 
nicotine responding by group. Figure 22 reports the dose 
response data for response rate by group. Figure 23 reports 
the overall results of the first and second dose response 
tests. 
DISCUSSION 
The analysis of variance (DV; % correct nicotine respond-
ing) produced significant differences for the between subject 
variable group, and the within subject variables dose and 
time. The interaction of dose by time was significant 
suggesting that the mechanism of action of acute tolerance 
(desensitization) was to some degree dictated by the specific 
dosing and/or time of injection. The significant interaction 
of group by dose adds further support for the desensitization 
model. 
The analysis of variance (DV; response rate) produced 
significant differences for the within subject variables dose 
and time. The interaction of dose by time was also signifi-
cant. These results suggest that the acute tolerance (desen-
sitization) phenomena is not related to response rates. 
The Tukey test (g<0.05) was used to analyze the interac-
tions between group by dose, and dose by time (percent correct 
nicotine responding). 
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The group by dose interaction showed that the desensitiz-
ing group was significantly less tolerant to the 1200 ug/kg 
and 1600 ug/kg doses than the non-desensitizing group. The 
dose by time interaction showed that the 90 minute time period 
produced a significant reduction in the percent correct 
nicotine responding for both groups. over the entire time 
course there was a downward stairstep effect as the concentra-
tion of the doses increased. 
The analysis of variance showed that there was no 
significant difference between groups over time, nor was the 
triple interaction of group by time by dose significant. 'le 
percent correct nicotine responding results suggest that the 
mechanism(s) of action of acute tolerance (desensitization) 
are effected by dose (concentration) and time course. The 
lack of significance for the group by time and the 
significance of group by dose suggest that the critical factor 
in the acute tolerance (desensitization) phenomena is the 
concentration of the dose given at time zero. 
The analysis of variance showed that for the dependent 
variable response rate the within subject variables time and 
dose were both significant. The interaction of dose by time 
was also significant suggesting that response rates were not 
a critical component of acute tolerance (desensitization). 
The fact that group as a main effect or as an interaction was 
never significant suggests that response rate is not a factor 
in the mechanism(s) of action of acute tolerance (desensitiza-
30 
ti on). 
GENERAL DISCUSSION AND CONCLUSIONS 
Nicotine and muscarine, both naturally occurring alka-
loids, have had a long and rich history in physiology and 
pharmacology research which has been central to our basic 
understanding of the physiology of the Autonomic Nervous 
System (ANS). From this research, a picture has emerged in 
which we view the parasympathetic division of ANS as having 
two types of cholinergic receptors, muscarinic and nicotinic. 
In addition these receptors appear to be sensitive to the 
endogenous ligand, acetylcholine (ACh) which appears essential 
for mediation of specific physiological events. The picture 
which emerged also viewed these receptors as being related 
serially in that the release of ACh at the nicotinic receptor 
will initiate a signal to a second neuron eliciting the 
release of ACh at a muscarinic receptor. This concept is 
essential to our understanding of the peripheral ANS, but this 
arrangement appears somewhat different when evaluated from the 
perspective of the role of these cholinergic neurons to brain 
function and behavior. 
The research of Domino (1967) showed that the behavioral 
effects of nicotine are elicited by an agonist effect at a 
select central nicotinic acetylcholingergic receptors ( nAChR' -
s). Domino further suggested that the nAChR was physiologi-
cally different from the muscarinic acetylcholinergic receptor 
(mAChR), but that both receptor types were responsive to ACh. 
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This research also suggested that these receptors had separate 
independent brain functions which indicated that these 
receptors may also be innervated by different neuronal path-
ways, unlike the arrangement in the peripheral ANS. 
In contrast to the mAChR, nAChR-induced physiological 
effects do not involve a second messenger system, but are 
mediated through the opening and closing of a cation channel 
(Fig. 1). Ochoa (1989) presents a model of ACh action at the 
nAChr which incorporates many of the basic concepts of the 
model of Katz and Thesleff (1957). Ochoa's model suggests 
that the synaptic release of acetylcholine first interacts 
with the nAChR to form an active state. The activated state 
then opens a cation channel at the postsynaptic membrane, 
which allows the influx of positively charged molecules. The 
nAChR is theorized to be rapidly converted to a deactivated 
state, thus closing the cation channel. This process appears 
to be specific to the nAChR and is essential to its physiolog-
ical role in the ANS. This secondary process appears to be 
related to a desensitization of the nAChR as the affinity of 
the receptor increases (Fig. 2). 
Using a drug discrimination paradigm, Meltzer and 
Rosecrans (1988), on the other hand, provided evidence that 
the relationship between acetylcholine and nicotine may not be 
as symbiotic as the research of Domino (1967) suggests. They 
showed that rats trained to discriminate nicotine (400 ug/kg) 
from saline failed to generalize to physostigmine (125-250 
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ug/kg), a cholinesterase inhibitor that retards the metabolism 
of acetylcholine. A group of rats trained to discriminate 
arecoline (a muscarinic agonist), however, clearly generalized 
to the ACh-elicited increase via physostigmine administration, 
suggesting that the m- and n-AChR were quite different, at 
least in their responsiveness to ACh and when nicotine is 
evaluated as a discriminative stimulus. Further evidence that 
these two cholinergic receptors are different was provided by 
the ability of mecamylamine, a nicotinic antagonist, to 
antagonize the discriminative stimulus properties of nicotine 
but not arecoline. On the other hand, atropine a muscarinic 
antagonist, antagonized the discriminative stimulus properties 
of arecoline, but not nicotine (Table 7) . The hypothesis 
which evolved from these investigations was that nicotine may 
not act on nicotinic cholinergic receptors sensitive to ACh. 
The suggestion was also made that nicotine may be acting on 
two cholinergic subtypes, one of which was sensitive to ACh. 
An explanation of these divergent findings has been 
difficult, but it has become evident that these data are not 
as unexpected if one considers the nature of the nAChR-linked 
cation channel as described by Ochoa et al. ( 1989). The 
scenario developed suggests that the physostigmine-elicited 
increase in ACh centrally, inadvertently desensitized the 
nAChR, inducing a "physiologically inhibitory state". Rats 
trained to discriminate nicotine, therefore, generalized to 
the vehicle state as the nAChR was inactivated. Arecoline 
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trained rats, on the other hand, were able to generalize to 
the physostigmine-elicited increase in ACh because the mAChR 
does not appear to desensitize as easily as is apparent with 
the nAChR. There are possibly other explanations of these 
findings, but the "desensitization hypothesis" seems most 
plausible at this time . From this scenario it would also seem 
plausible that nicotine should induce a desensitization of the 
nAChR as well, especially if its actions were tied to ACh. 
Thus, nicotine should be able to antagonize nicotine, better 
defined as acute tolerance. 
The drug discrimination paradigm presents an ideal 
paradigm to test and extend this hypothesis. The nature of 
the nicotine disriminative stimulus (OS) has been well 
established (Table 7). The OS is selective and sensitive to 
nicotine, parallels brain nicotine concentrations, and is 
separable from other cholinergic receptor-acting 
In addition, this paradigm is very resistant to other 
clearly 
drugs. 
drug effects such as drug-induced behavioral disruption and 
chronic tolerance. In this paradigm, rats need to become 
behaviorally tolerant to nicotine to be able to press the 
lever for food, but can't become tolerant to the OS if they 
are to continue to choose the correct-lever for positive 
reinforcement. Thus, this procedure is extremely reliable 
which permits one to separate pharmacological mechanisms of 
drug action (such as in vivo receptor desensitization) from 
behavioral mechanisms. 
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The first goal of this research was to demonstrate that 
nicotine could induce acute tolerance using the drug discrimi-
nation paradigm. A time course methodology was chosen in 
which rats trained to discriminate nicotine were administered 
a challenge dose of nicotine (800 ug/kg, s.c.) at various time 
points (15, 30, 60, 90, 120, 150, 180, 210, 240 minutes) prior 
to testing the ability of these rats to detect the training 
dose of nicotine (400 ug/kg). Each time point was tested on 
a different day, and the order was determined using a Latin 
Square design. Desensitization, or nicotine-induced acute 
tolerance was defined as a 50% reduction in the ability of a 
subject to detect nicotine. The data obtained indicated that 
40 to 50% of the rats evaluated exhibited acute tolerance 
(Figures 4-6). Most important was the observation that not 
all rats exhibited acute tolerance, and we were able to 
classify these animals as to desensitive-prone and non-
desensitizers. Furthermore, desensitive-prone rats exhibited 
a temporal differential sensitivity which was replicatable in 
almost every case . Thus, rats showed different times for 
desensitization between challenge and test dose. The average 
time for desensitization to develop appeared to be 90 min. 
This is interpreted to mean that the desensitization process 
at the nAChR is time-limited for each rat and that not all 
rats appear able to exhibit desensitization. This is an 
extremely important observation which suggests that the nAChR-
linked channel apparatus varies between rats which may be 
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essential to nicotine's variable behavioral effects. 
The second goal of this research was to learn more about 
the mechanism of desensitization (acute tolerance) which may 
also be tied to understanding why nicotine did not generalize 
to physostigmine. Two possibilities exist as to why physo-
stigmine failed to generalize with nicotine. First, the 
discriminative stimulus effect of nicotine may not be mediated 
by a mechanism( s) directly linked to acetylcholine . Secondly, 
the discriminative stimulus effect is mediated by an nAChR, 
but the rapid increase of acetylcholine caused by physostig-
mine desensitized the receptor which induced a vehicle state. 
If acetylcholine is the primary neurotransmitter associated 
with the discriminative cue, then physostigmine injected at 
time zero should be capable of antagonizing nicotine at some 
later time point. Support for this concept was observed in 
seven rats challenged with both nicotine and physostigmine 
(Figures 10-13). This research, therefore, provides presump-
tive evidence that nicotine is acting at a cholinergic 
receptor sensitive to ACh which is susceptible to rapid 
desensitization. Whether nicotine is acting my mimicking this 
receptor, or inducing release of ACh presynaptically remains 
unknown. In addition we are not sure as to the location of 
these nAChR's, and whether they are located on mainly pre-
and/or postsynaptic elements of the cholinergic neuron. 
The third. phase of this research involved answering an 
additional question concerning the desensitization process in 
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vivo. A major concern was the apparent "all or none" nature 
of acute tolerance; some rats did not exhibit tolerance. The 
question concerns whether we are dealing more with a rate 
process which is contingent upon dose. Thus, will the non-
desensi tizer exhibit acute tolerance at some higher dose? 
Experiment two was designed to evaluate the dose-response 
characteristics of nicotine-elicited acute tolerance. The 
results suggest that there is some merit to the concept that 
dose or nicotine level at the AChR is an important consider-
ation. In fact all such pharmacological processes should be 
dose-related at some point. In support of this the number of 
rats exhibiting tolerance increased at each challenge dose 
from 800, 1200, 1600 ug/kg.(Table 6). 
Percent nicotine-correct responding suggests that the 
mechanism(s) of action of acute tolerance (desensitization) 
are effected by dose (concentration) and time course. The 
lack of significance of group by dose suggests that the 
critical factor is the concentration of the dose given at time 
zero. The response rate data showed that time and dose were 
both significant and the interaction of the two was signifi-
cant. The fact that group as a main effect or as an interac-
tion was never significant suggests that response rate is not 
a factor in the mechanism( s) of action of acute tolerance 
(desensitization). This is an extremely important factor as 
it demonstrates that the ability to detect a drug is indepen-
dent of behavioral disruption. This also supports the 
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contention that we are studying pharmacological mechanisms 
such as desensitization rather than events contingent upon 
some behavioral effect. Thus, rats are not able to detect 
nicotine following a large dose of nicotine just because they 
are also disrupted; the explanation for this antagonism (acute 
tolerance) is that nicotine induced a desensitization of the 
nAChR. 
This research has provided evidence of the specific 
nature of the interaction of nicotine with its nAChR. The 
behavioral paradigm used is reliable and appears to be 
analogous to what a human perceives when he or she is adminis-
tered nicotine, usually through some tobacco product. This 
paradigm also has relevance to studies evaluating neuromolecu-
lar mechanisms of drug action. We have provided evidence that 
nicotine is producing its effects at some nAChR which can be 
evaluated in viyo. The methodology is now available to 
evaluate nicotine's acute and chronic effects via the applica-
tion of drugs centrally with the use of specific brain probes 
(microdialysis cannula). We can evaluate the effects of drugs 
on specific structures while rats are in the process of 
detecting a specific drug state, and we can at the same time, 
evaluate the effects of the OS on endogenous chemicals through 
the same probes. Thus, this methodology has many applications 
for future research employing in vitro approaches with an .in 
vi.YQ paradigm to answer specific questions concerning mecha-
nism's of drug action. 
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The last point concerns the relevance of this research to 
the real world. Besides using such approaches in conjunction 
with more molecular approaches, this research has much 
relevance to the drug user, in this case those who use 
tobacco. There are many issues in smoking and the ability of 
nAChR to desensitize may be extremely important to under-
standing some of these issues. First, desensitization may be 
useful in explaining rate of smoking behavior. Thus, one may 
smoke at specific intervals because the nAChR in that individ-
ual has a specific desensitization time. Secondly, an 
individual who possesses an nAChR which does not desensitize 
may get a full nicotine dose which is aversive and who may 
never smoke again because of this initial effect. Some 
desensitizers, on the other hand, may become heavy nicotine-
dependent uses because the nicotine effect is extremely 
positive to which acute tolerance is not apparent. Thirdly, 
because of predisposition for a high rate of desensitization, 
an individual may smoke with no aversive effects and become a 
life time user of tobacco. Thus, there are several implica-
tions of this research to human drug dependency on nicotine 
via tobacco. Interestingly, there have been indications of 
people becoming dependent on Nicoret gumr which is used as a 
tobacco substitute in tobacco cessation treatment (Rosecrans, 
unpublished observations). Thus, would the same principles 
apply. An important aspect of this hypothesis is that it is 
testable in humans. Humans can be trained to discriminate 
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different doses of nicotine, and we can evaluate rates of 
desensitization via nicotine challenges in individual smokers. 
Another issue concerns select populations which smoke. 
It seems that smoking and depression are positively correlat-
ed, and schizophrenics can become obsessive smokers (beyond 
dependent). The question concerns whether nicotine may be 
affecting other neurochemical systems important to these 
behavioral disorders. Do people smoke to relieve depression 
or to control their craziness? Evidence to support such a 
contention is apparent from studies which indicate that 
nAChR's are located on many pre-synaptic non-cholinergic 
receptors such as dopaminergic and serotoninergic neurons. 
Thus, nicotine can modulate other non-cholinergic neurons, 
especially if we consider what we have been studying here, 
nAChR desensitization. It can be envisioned that nicotine is 
capable of inducing a physiological antagonism of several of 
these system via its molecular effects at the nAChR. Nico-
tine, therefore, could modulate a variety of neuron popula-
tions in the brain via an agonist and/or antagonist (desensi-
tization) process. Humans who use nicotine chronically appear 
to have most of their neurons in the desensitized state 
indicating some long term effects. This work has been used to 
explain why smoker's are less likely to develop parkinson's 
disease (Rosecrans and Karan, 1992). The nAChR has also been 
implicated in alzheimer's as well and several workers are 
evaluating the long term effects of nicotine on learning and 
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memory in these individuals. Thus, nicotine, while scorned 
because of its presence in tobacco, and because of the 
toxicological effects of tobacco, has many subtle but powerful 
effects which have the potential to be utilized in several 
abnormal behavioral and neurological conditions. Its poten-
tial as a therapeutic agent is quite great if we consider the 
numbers of people who have used tobacco products and consider 
the many reasons why tobacco has been so popular since it was 
farmed in Virginia. 
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53 
0 
0 
0.14 
0
.36 
91 
12 
55 
1
7
 
20 
0.09 
0.4 
87 
20 
46 
33 
0.03 
0.6 
25 
62 
7 
0.03 
0.29 
1 
0 
0.09 
0.39 
60 
23 
10 
5 
0.07 
0.13 
100 
22 
52 
48 
0.08 
0.48 
71 
45 
47 
47 
0.11 
0.27 
90 
2 
59 
21 
31 
0.05 
0.22 
56 
44 
44 
0.05 
0.34 
6 
37 
0
.03 
0.24 
87 
9 
AVG 
22 
28 
0.08 
0.33 
78 
1
5
 
SEM 
5 
5 
0.01 
0.03 
6 
2 
TABLE 2 
seLII-eLQI A~Q~A: 
(DV-% correct nicotine responding; N-20; mean-78.5 
BETWEEN SUBJECT VARIABLE 
SOURCE SUM-OF-SQUARES OF F-RATIO p 
GROUP 20094 1 13.568 0.0020 
ERROR 26657 18 
WITHIN SUBJECT V AAIABLES 
· .:: 
~ 
DOSE (0.8, 1.2, 1.6mg/kg) 9652 2 11 .156 0.0003 
GROUP*OOSE 5275 2 6.097 0.0055 
ERROR 15574 36 
TIME 19832 4 11.050 0.0000 
GROUP*TIME 3609 4 2.011 0.1012 
ERROR 32305 72 
OOSE*TIME 89198 8 27.225 0.0000 
GROUP*TIME*DOSE 5590 8 1.706 0.1014 
ERROR 58975 144 
TABLE 3 
SPLIT-PLOT ANOVA: 
(DY-number of responses/second; N-20; mean-0.17 
BETWEEN SUBJECT VARIABLE 
SOURCE 
GROUP 
ERROR 
SUM-OF-SQUARES OF F-RA TIO p 
3428 
20505 
WITHIN SUBJECT VARIABLES 
SJ.Rl: . -- '·'· ~ 
DOSE ~' 423 ""-' --
GROUP*DOSE 132 
ERROR 2135 
TIME 1431 
GROUP*TIME 157 
ERROR 5509 
DOSE*TIME 7319 
GROUP*OOSE*TIME 674 
ERROR 12449 
1 3.009 0.0968 
18 
2 : .. 3.568 ' 0.0377 
2 1.110 0.3412 
36 
4 4.6n 0.0024 
4 0.513 
72 
8 10.583 0.0000 
8 0.975 
144 
TABLE 4 
OVERALL MEANS: (OV· % correct nicotine responding) 
EFFECT: GROUP 
OESENSITIZERS 
61.97 
NON-OESENSITIZERS 
78.67 
EFFECT: OC>SE 
800 UG/KG 
65.21 
EFFECT: TIME 
60 MIN . 90 MIN · 
54.42 - 74-.50 
EFFECT: GAot.JPDose 
0 800 . • t> 1200 -
62.35 67.83 
ND 800 ND 1200 
67.12= aa.n 
EFFECT: GROUP*TIME 
0-60 0-90 
50.92 66.13 
ND-60 N0-90 
56.75 80.08 
EFFECT: OOSE*TIME 
800-60 800-90 
72.85 76.35 
1200 UG/KG 
80.39 
120 MIN 
78.27 
01600 
55.73 
ND 1600 
80.13 
0-120 
64.92 
N0-120 
87.17 
800-120 
87.75 
1200-60 1200-90 1200-120 
84.60 78.70 86.25 
1600-60 1600-90 1600-120 
78.65 68.45 60.80 
150 MIN 
1600 UG/KG 
70.37 
180 MIN 
75.~ n.23 
.•. ;,'·~. ,_ .. .. ;: 
0-150 D-180 
66.42 61.46 
ND-150 N0-180 
81.61 87.75 
800-150 800-180 
79.45 82.50 
1200-150 1200-180 
75.80 76.60 
1600-150 1600-180 
71.35 72.60 
TABLE 5 
OVERALL MEANS: (OV-responses/second) 
EFFECT: GROUP 
OESENSITIZERS 
0.12 
EFFECT: IX>SE 
NON-OESENSITIZERS 
1.19 
800 UG/KG 1200 UG/KG 1600 UG/KG 
0.18 0.16 0.15 
EFFECT: TIME 
60 MIN·' -· 90 MIN 120 MIN 150 MIN ; 180 MIN 
0.12 0.17 
EFFECT: GROUPiX>SE 
0-800 
0.13 
N0-800 
0.22 
EFFECT: GROUP"TIME 
0-60 0-90 
0.09 0.12 
N0-60 N0-90 
0.14 0.21 
EFFECT: IX>SE*TIME 
800-60 800-90 
0.21 0.22 
1200•60 .· 1200-90 
0.22 0.15 
1600-6().· 1600-90 
0.14 0.14 
0.16 
0-1200 
0.13 
N0-1200 
0.18 
0-120 
0.19 
0-1600 
0.11 
ND-1600 
0.18 . 
0.17 
0-150 0-180 
0.12 0.15 0.13 
N0-120 N0-150 N0-180 
0.19 0.23 0.19 
800-120 800-150 800-180 
0.23 0.24 0.22 
1200-120 1200-150 1200-180 
0.14 0.15 0.13 
1600-120 1600-150 1600-180 
0.12 0.20 0.15 
TABLE 6 
GROUP SHIFTS BY POSE: 
DOSE 800 ug/kg 1200 ug/kg 1600 ug/kg 
DESENSITIZERS 4 8 
NON-DESENSITIZERS 19 16 12 
TABLE 7 
Summ-ry of the Current Status of the Mechaninu of Action and 
Spedldty of the DS Properties of Arecoline and Nicotine 
Properda of DS 
DS dose-related 
Antagonized by 
Note Antagonized by 
Generalize to 
Does not 
Generalize to 
Brain Sites of 
Action 
Other Biogenic 
Amines involved 
Nicotine 
Yes 
Mecamylamine 
All non<holinergic Receptor 
Antagonisu 
Tested 8c 
Hexamethonium 
S-PMP 
(+)-Nicotine 
Amphetamine 
(Partial) 
Nornicotine 
(Partial) -
Cytisine , 
Cotinine • 
(Partial) -
Physostigmine 
Arecoline 
Diazepam 
Caffeine 
-cLobeline-
Hippocampus 
Reticular Formation 
Presynaptic 
Dopamine sites 
•.c-•-
Arecoline 
Yes 
Atropine' 
All non<holinergic Receptor 
Antagonisu 
Tested le 
Methyl At~ine 
Physoatigmine 
Oxotremorine 
Pilocarpine 
Nicotine 
Amphetamine 
Neoltigmine 
N.A. 
N.A. 
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